PF-Atlas › Clinical Trials › NCT03925194
A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF
Anakinra · Phase 2
Registry ID
NCT03925194
Phase
Phase 2
Status
Recruiting
Drug / intervention
Anakinra
Sponsor
Heidelberg University
Start
2022-12-01
Enrollment
52
Locations
3
About this trial
OBJECTIVES Primary: To evaluate efficacy of treatment with anakinra in subjects with CF who are ≥ 12 years of age by means of lung clearance index (LCI). Secondary To evaluate safety and tolerability of treatment with anakinra as well as to investigate further effects of anakinra on lung function and quality of life (QOL) in subjects with CF.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT03925194 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.